38.63

3.55% -1.42

After Hours: 38.63

Soleno Therapeutics Inc (SLNO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Soleno Therapeutics Inc stock is traded at $38.63, with a volume of 1.22M. It is down -3.55% in the last 24 hours and down -7.01% over the past month. Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Previous Close:

$40.05

Open:

$40.37

24h Volume:

1.22M

Relative Volume:

0.77

Market Cap:

$2.07B

Revenue:

Net Income/Loss:

$-38.99M

P/E Ratio:

-12.89

EPS:

-2.9966

Net Cash Flow:

$-24.94M

1W Performance:

-2.40%

1M Performance:

-7.01%

6M Performance:

-53.66%

1Y Performance:

-23.12%

1-Day Range:

$37.53

$40.37

1-Week Range:

$37.53

$41.84

52-Week Range:

$37.53

$90.32

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name

Soleno Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

650-213-8444

Address

100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA

Employee

152

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

SLNO's Discussions on Twitter

Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLNO Soleno Therapeutics Inc	38.63	2.15B	0	-38.99M	-24.94M	-2.9966
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-25	Initiated	Wolfe Research	Outperform
Oct-07-25	Initiated	Goldman	Buy
Aug-20-25	Initiated	Wells Fargo	Overweight
Jun-23-25	Initiated	TD Cowen	Buy
Mar-05-25	Resumed	Stifel	Buy
Dec-02-24	Reiterated	Robert W. Baird	Outperform
Dec-02-24	Reiterated	Stifel	Buy
Sep-03-24	Initiated	H.C. Wainwright	Buy
May-10-24	Initiated	Robert W. Baird	Outperform
Feb-05-24	Initiated	Piper Sandler	Overweight
Jan-23-24	Initiated	Stifel	Buy
Nov-21-23	Resumed	Guggenheim	Buy
Sep-29-20	Initiated	Guggenheim	Buy
Jan-10-20	Initiated	Craig Hallum	Buy
Dec-23-19	Initiated	Oppenheimer	Outperform
Feb-13-18	Reiterated	Maxim Group	Buy

View All

Soleno Therapeutics Inc Stock (SLNO) Latest News

Feb 12, 2026

Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year LowTime to Sell? - MarketBeat

Feb 12, 2026

SLNO: Strong market uptake, stable safety, and robust reimbursement support ongoing growth - TradingView

Feb 12, 2026

Soleno Therapeutics stock hits 52-week low at 37.95 USD - Investing.com

Feb 12, 2026

Feb 11, 2026

Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET - The Manila Times

Feb 11, 2026

Rare disease biotech Soleno sets Feb. 25 call on 2025 results - Stock Titan

Feb 11, 2026

Feb 07, 2026

Soleno Therapeutics prices $200M public offering - MSN

Feb 07, 2026

Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress

Feb 07, 2026

Feb 05, 2026

Pullback Watch: Why is Soleno Therapeutics Inc. stock going downMarket Growth Report & Fast Moving Market Watchlists - baoquankhu1.vn

Feb 05, 2026

Why a biotech is drawing attention to a rare disease at the Super Bowl - Medical Marketing and Media

Feb 05, 2026

Soleno Therapeutics (NASDAQ:SLNO) Lowered to "Hold" Rating by Zacks Research - MarketBeat

Feb 05, 2026

(SLNO) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Feb 05, 2026

What Soleno Therapeutics (SLNO)'s VYKAT XR Momentum and 2025 Outlook Could Mean For Shareholders - Sahm

Feb 05, 2026

Feb 03, 2026

VYKAT XR Launch Momentum Could Be A Game Changer For Soleno Therapeutics (SLNO) - Yahoo Finance

Feb 03, 2026

A Look At Soleno Therapeutics (SLNO) Valuation As VYKAT XR Launch Shapes A “Transformational” 2025 - Yahoo Finance

Feb 03, 2026

A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates - Sahm

Feb 03, 2026

Published on: 2026-02-03 13:03:09 - baoquankhu1.vn

Feb 03, 2026

Feb 02, 2026

Down 18.3% in 4 weeks, here's why Soleno Therapeutics (SLNO) looks ripe for a turnaround - MSN

Feb 02, 2026

Soleno Therapeutics (NASDAQ:SLNO) Stock Price Up 8.3%Time to Buy? - MarketBeat

Feb 02, 2026

Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next - TechStock²

Feb 02, 2026

Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround - Yahoo Finance

Feb 02, 2026